FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Des Richardson

Research Profile

Chemicals & Drugs

Anatomy

Co-author Network

Publications

TOP 3
Darius J R Lane; Michael L-H Huang; Des R Richardson
Hepcidin, show some self-control! How the hormone of iron metabolism regulates its own expression.
Darius J R Lane; Sherin Chikhani; Vera Richardson; Des R Richardson
Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism.
Zaklina Kovacevic; Goldie Y L Lui; Sherin Chikhani; Sutharshani Sivagurunathan; Des R Richardson
The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Des Richardson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Darius J R Lane; Michael L-H Huang; Des R Richardson
Hepcidin, show some self-control! How the hormone of iron metabolism regulates its own expression.
The Biochemical journal 2013;452(2):e3-5.
2013: Darius J R Lane; Sherin Chikhani; Vera Richardson; Des R Richardson
Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism.
Biochimica et biophysica acta 2013;1833(6):1527-41.
2013: Zaklina Kovacevic; Goldie Y L Lui; Sherin Chikhani; Sutharshani Sivagurunathan; Des R Richardson
The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways.
Antioxidants & redox signaling 2013;18(8):874-87.
2013: Angelica M Merlot; Danuta S Kalinowski; Des R Richardson
Novel chelators for cancer treatment: where are we now?
Antioxidants & redox signaling 2013;18(8):973-1006.
2013: Adeline Y Lukmantara; Danuta S Kalinowski; Naresh Kumar; Des R Richardson
Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy.
Bioorganic & medicinal chemistry letters 2013;23(4):967-74.
2013: Katie M Dixon; Q Dong; Z Kovacevic; G Y L Lui; Stephen J Assinder; Z Chen; M Yao; D Zhang; Des R Richardson
Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
British journal of cancer 2013;108(2):409-19.
2013: Jing Sun; Daohai Zhang; Qian Zhao; Minhua Zheng; Ying Zheng; Zaklina Kovacevic; Des R Richardson
Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway.
Molecular pharmacology 2013;83(2):454-69.
2013: Ján Stariat; Danuta S Kalinowski; Jiří Klimeš; Petra Kovaříková; Radim Kučera; Des R Richardson; Raimo A Ketola
Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry.
Analytical and bioanalytical chemistry 2013;405(5):1651-61.
2013: Christian Stefani; Des R Richardson; Paul V Bernhardt; Elaine Gutierrez; Patric J Jansson; Danuta S Kalinowski
Alkyl substituted 2'-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation.
Journal of medicinal chemistry 2013;56(1):357-70.
2013: Darius J R Lane; Federica Saletta; Yohan Suryo Rahmanto; Zaklina Kovacevic; Des R Richardson
N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion.
PloS one 2013;8(2):e57273.
2013: Danuta S Kalinowski; Zaklina Kovacevic; Patric J Jansson; Des R Richardson
The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.
Redox report : communications in free radical research 2013;18(2):48-50.
2013: Goldie Y L Lui; Peyman Obeidy; Danae M Sharp; Chris Tselepis; Samuel J Ford; Patric J Jansson; Danuta S Kalinowski; Zaklina Kovacevic; David B Lovejoy; Des R Richardson
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Molecular pharmacology 2013;83(1):179-90.
2012: Megan Whitnall; Federica Saletta; Tim G St Pierre; Yohan Suryo Rahmanto; Adam J Fleming; Lucía Gutiérrez; Michael L-H Huang; Francisco J Lázaro; Hiu Chuen Lok; Marc R Mikhael; Prem Ponka; Des R Richardson
Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(50):20590-5.
2012: Zufan Debebe; Victor Roland Gordeuk; Danuta S Kalinowski; Meseret Ashenafi; W Malcolm Byrnes; David B Lovejoy; Sergei Nekhai; Des R Richardson; Pradeep K Karla
Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;906():25-32.
2012: Maciej Serda; Agnieszka Szurko; Alicja Ratuszna; Des R Richardson; Danuta S Kalinowski; Zaklina Kovacevic; Angelica M Merlot; Anna Mrozek-Wilczkiewicz; Robert Musiol; Namfon Pantarat; Jaroslaw Polanski
Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.
Bioorganic & medicinal chemistry letters 2012;22(17):5527-31.
2012: David B Lovejoy; Peyman Obeidy; Thomas Prichard; Maram T Basha; Paul V Bernhardt; Patric J Jansson; Danuta S Kalinowski; Nicole Seebacher; Danae M Sharp; Philip C Sharpe; Christian Stefani; Des R Richardson
Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.
Journal of medicinal chemistry 2012;55(16):7230-44.
2012: Cheng Li; Maria E Lönn; Ghassan J Maghzal; Des R Richardson; Gregory J Anderson; David M Frazer; Barry Halliwell; Shane R Thomas; Xiangcong Xu; Roland Stocker
Sustained expression of heme oxygenase-1 alters iron homeostasis in nonerythroid cells.
Free radical biology & medicine 2012;53(2):366-74.
2012: Patricia Quach; Philip C Sharpe; Maram Talal Basha; Paul V Bernhardt; Elaine Gutierrez; Patric J Jansson; Danuta S Kalinowski; David B Lovejoy; Des R Richardson
Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.
Molecular pharmacology 2012;82(1):105-14.
2012: Maram T Basha; Jy D Chartres; Danuta S Kalinowski; Aminul Huq Mirza; Namfon Pantarat; Des R Richardson; Mohammad Akbar Ali; Paul V Bernhardt
Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity.
Dalton transactions (Cambridge, England : 2003) 2012;41(21):6536-48.
2012: Zhiqiang Chen; Zaklina Kovacevic; Fei Yue; Daohai Zhang; Minhua Zheng; Des R Richardson
The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1).
The Journal of biological chemistry 2012;287(21):17016-28.
2012: Ján Stariat; Katerina Vávrová; Milan Nobilis; Des R Richardson; Vít Sesták; Danuta S Kalinowski; Jiří Klimeš; Zuzana Kollárová; Petra Kovaříková
LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT.
Analytical and bioanalytical chemistry 2012;403(1):309-21.
2012: Yohan Suryo Rahmanto; Vera Richardson; Danuta S Kalinowski; Darius J R Lane; Hiu Chuen Lok; Des R Richardson
Nitrogen monoxide (NO) storage and transport by dinitrosyl-dithiol-iron complexes: long-lived NO that is trafficked by interacting proteins.
The Journal of biological chemistry 2012;287(10):6960-8.
2012: Yohan Suryo Rahmanto; Yu Yu; Sumeet Bal; Kim H Loh; Des R Richardson
Melanotransferrin: search for a function.
Biochimica et biophysica acta 2012;1820(3):237-43.
2012: Danmei Gao; Yuan Kun Lee; Thomas C Putti; Des R Richardson; I Fon Bambang; Daohai Zhang
ERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPK.
Laboratory investigation; a journal of technical methods and pathology 2012;92(2):200-13.
2012: Colin Correnti; Margaret A Holmes; Brett K Kaiser; Kenneth N Raymond; Des R Richardson; Vera Richardson; Mario Ruiz; Allyson K Sia; Ashok D Bandaranayake; Jonathan Barasch; Matthew C Clifton; Yohan Suryo Rahmanto; Žaklina Kovačević; Roland K Strong
Siderocalin/Lcn2/NGAL/24p3 does not drive apoptosis through gentisic acid mediated iron withdrawal in hematopoietic cell lines.
PloS one 2012;7(8):e43696.
2012: Yu Yu; Yohan Suryo Rahmanto; F Saletta; E Gutierrez; Z Kovacevic; P Obeidy; Des R Richardson
Iron chelators for the treatment of cancer.
Current medicinal chemistry 2012;19(17):2689-702.
2011: Michael Li-Hsuan Huang; Darius J R Lane; Des R Richardson
Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease.
Antioxidants & redox signaling 2011;15(12):3003-19.
2011: Federica Saletta; Aritee R Siafakas; Yohan Suryo Rahmanto; Des R Richardson
Cellular iron depletion and the mechanisms involved in the iron-dependent regulation of the growth arrest and DNA damage family of genes.
The Journal of biological chemistry 2011;286(41):35396-406.
2011: Christian Stefani; Philip C Sharpe; Paul V Bernhardt; Patric J Jansson; Danuta S Kalinowski; David B Lovejoy; Gaya Punnia-Moorthy; Des R Richardson
Halogenated 2'-benzoylpyridine thiosemicarbazone (XBpT) chelators with potent and selective anti-neoplastic activity: relationship to intracellular redox activity.
Journal of medicinal chemistry 2011;54(19):6936-48.
2011: Zaklina Kovacevic; David B Lovejoy; Sherin Chikhani; Des R Richardson
Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer.
Molecular pharmacology 2011;80(4):598-609.
2011: David B Lovejoy; Prem Ponka; Ulf T Brunk; Patric J Jansson; Jacky Wong; Des R Richardson
Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.
Cancer research 2011;71(17):5871-80.
2011: Yu Yu; Clare L Hawkins; Yohan Suryo Rahmanto; Des R Richardson
The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity.
Molecular pharmacology 2011;79(6):921-31.
2011: Zaklina Kovacevic; Sutharshani Sivagurunathan; Helena Mangs; Sherin Chikhani; Daohai Zhang; Des R Richardson
The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms.
Carcinogenesis 2011;32(5):732-40.
2011: Yu Yu; Des R Richardson
Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1.
The Journal of biological chemistry 2011;286(17):15413-27.
2011: Zaklina Kovacevic; Yu Yu; Des R Richardson
Chelators to the rescue: different horses for different courses!
Chemical research in toxicology 2011;24(3):279-82.
2011: Luca Piali; Des R Richardson
G-protein coupled receptors: drug targets of key importance.
Current topics in medicinal chemistry 2011;11(6):608.
2011: Paul V Bernhardt; Des R Richardson
Metal chelation.
Current topics in medicinal chemistry 2011;11(5):482.
2011: Zaklina Kovacevic; Danuta S Kalinowski; David B Lovejoy; Yu Yu; Philip C Sharpe; Paul V Bernhardt; Yohan Suryo Rahmanto; Des R Richardson
The medicinal chemistry of novel iron chelators for the treatment of cancer.
Current topics in medicinal chemistry 2011;11(5):483-99.
2011: Philip C Sharpe; Des R Richardson; Danuta S Kalinowski; Paul V Bernhardt
Synthetic and natural products as iron chelators.
Current topics in medicinal chemistry 2011;11(5):591-607.
2011: Zufan Debebe; Tatyana Ammosova; Denitra Breuer; David B Lovejoy; Danuta S Kalinowski; Krishna Kumar; Marina Jerebtsova; Patricio Ray; Fatah Kashanchi; Victor Roland Gordeuk; Des R Richardson; Sergei Nekhai
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9.
Molecular pharmacology 2011;79(1):185-96.
2011: Daohai Zhang; Des R Richardson
Endoplasmic reticulum protein 29 (ERp29): An emerging role in cancer.
The international journal of biochemistry & cell biology 2011;43(1):33-6.
2010: Katerina Brychtova; Radka Opatrilova; Ivan Raich; Danuta S Kalinowski; Lenka Dvorakova; Lukas Placek; Jozef Csollei; Des R Richardson; Josef Jampilek
Investigating the activity of 2-substituted alkyl-6-(2,5-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers.
Bioorganic & medicinal chemistry 2010;18(24):8556-65.
2010: Federica Saletta; Yohan Suryo Rahmanto; Des R Richardson
The translational regulator eIF3a: the tricky eIF3 subunit!
Biochimica et biophysica acta 2010;1806(2):275-86.
2010: Jan Otevrel; Zuzana Mandelova; Matus Pesko; Jiahui Guo; Katarina Kralova; Frantisek Sersen; Marcela Vejsova; Danuta S Kalinowski; Zaklina Kovacevic; Aidan Coffey; Jozef Csollei; Des R Richardson; Josef Jampilek
Investigating the spectrum of biological activity of ring-substituted salicylanilides and carbamoylphenylcarbamates.
Molecules (Basel, Switzerland) 2010;15(11):8122-42.
2010: Patric J Jansson; Clare L Hawkins; David B Lovejoy; Des R Richardson
The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study.
Journal of inorganic biochemistry 2010;104(11):1224-8.
2010: Angelica M Merlot; Namfon Pantarat; David B Lovejoy; Danuta S Kalinowski; Des R Richardson
Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer.
Molecular pharmacology 2010;78(4):675-84.
2010: Qinghua Miao; Dongxue Xu; Zhi Wang; Li Xu; Tiewei Wang; Yan Wu; David B Lovejoy; Danuta S Kalinowski; Des R Richardson; Guangjun Nie; Yuliang Zhao
Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents.
Biomaterials 2010;31(28):7364-75.
2010: William C J Singleton; Kelly T McInnes; Michael A Cater; Wendy R Winnall; Ross McKirdy; Yu Yu; Philip E Taylor; Bi-Xia Ke; Des R Richardson; Julian F B Mercer; Sharon La Fontaine
Role of glutaredoxin1 and glutathione in regulating the activity of the copper-transporting P-type ATPases, ATP7A and ATP7B.
The Journal of biological chemistry 2010;285(35):27111-21.
2010: Patric J Jansson; Philip C Sharpe; Paul V Bernhardt; Des R Richardson
Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity.
Journal of medicinal chemistry 2010;53(15):5759-69.
2010: Petra Bendova; Eliska Mackova; Pavlina Haskova; Anna Vavrova; Eduard Jirkovsky; Martin Sterba; Olga Popelova; Danuta S Kalinowski; Petra Kovarikova; Katerina Vavrova; Des R Richardson; Tomas Simunek
Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.
Chemical research in toxicology 2010;23(6):1105-14.
2010: Des R Richardson; Darius J R Lane; Erika M Becker; Michael L-H Huang; Megan Whitnall; Alex D Sheftel; Yohan Suryo Rahmanto; Prem Ponka
Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(24):10775-82.
2010: Ján Stariat; Petra Kovaríková; Jirí Klimes; Danuta S Kalinowski; Des R Richardson
Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT.
Analytical and bioanalytical chemistry 2010;397(1):161-71.
2010: Anna Mrozek-Wilczkiewicz; Danuta S Kalinowski; Robert Musiol; Jacek Finster; Agnieszka Szurko; Katarzyna Serafin; Magdalena Knas; Sishir K Kamalapuram; Zaklina Kovacevic; Josef Jampilek; Alicja Ratuszna; Joanna Rzeszowska-Wolny; Des R Richardson; Jaroslaw Polanski
Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones.
Bioorganic & medicinal chemistry 2010;18(7):2664-71.
2010: Des R Richardson; Michael L-H Huang; Megan Whitnall; Erika M Becker; Prem Ponka; Yohan Suryo Rahmanto
The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia.
Journal of molecular medicine (Berlin, Germany) 2010;88(4):323-9.
2010: Darius J R Lane; Des R Richardson
Frataxin, a molecule of mystery: trading stability for function in its iron-binding site.
The Biochemical journal 2010;426(2):e1-3.
2010: Federica Saletta; Egarit Noulsri; Yohan Suryo Rahmanto; Des R Richardson
Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53.
Molecular pharmacology 2010;77(3):443-58.
2010: Joe Liu; Daniel Obando; Liam G Schipanski; Ludwig K Groebler; Paul K Witting; Danuta S Kalinowski; Des R Richardson; Rachel Codd
Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
Journal of medicinal chemistry 2010;53(3):1370-82.
2009: Michael Li-Hsuan Huang; Erika M Becker; Megan Whitnall; Prem Ponka; Yohan Suryo Rahmanto; Des R Richardson
Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(38):16381-6.
2009: Yu Yu; Danuta S Kalinowski; Zaklina Kovacevic; Aritee R Siafakas; Patric J Jansson; Christian Stefani; David B Lovejoy; Philip C Sharpe; Paul V Bernhardt; Des R Richardson
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
Journal of medicinal chemistry 2009;52(17):5271-94.
2009: Danuta S Kalinowski; Patricia Quach; Des R Richardson
Thiosemicarbazones: the new wave in cancer treatment.
Future medicinal chemistry 2009;1(6):1143-51.
2009: Yohan Suryo Rahmanto; Des R Richardson
Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): no overt alteration in phenotype.
Biochimica et biophysica acta 2009;1793(7):1210-7.
2009: Des R Richardson; Danuta S Kalinowski; S Lau; P J Jansson; David B Lovejoy
Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents.
Biochimica et biophysica acta 2009;1790(7):702-17.
2009: Gabriela Peslova; Jiri Petrak; Katerina Kuzelova; Ivan Hrdy; Petr Halada; Philip W Kuchel; Shan Soe-Lin; Prem Ponka; Robert Sutak; Erika Becker; Michael Li-Hsuan Huang; Des R Richardson; Yohan Suryo Rahmanto; Daniel Vyoral
Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood.
Blood 2009;113(24):6225-36.
2009: A Rosemary Siafakas; Des R Richardson
Growth arrest and DNA damage-45 alpha (GADD45alpha).
The international journal of biochemistry & cell biology 2009;41(5):986-9.
2009: Des R Richardson; Danuta S Kalinowski; Vera Richardson; Philip C Sharpe; David B Lovejoy; Mohammad Islam; Paul V Bernhardt
2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.
Journal of medicinal chemistry 2009;52(5):1459-70.
2009: Egarit Noulsri; Des R Richardson; Surada Lerdwana; Suthat Fucharoen; Tetsuo Yamagishi; Danuta S Kalinowski; Kovit Pattanapanyasat
Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.
American journal of hematology 2009;84(3):170-6.
2009: Stephen J Assinder; Qihan Dong; Helena Mangs; Des R Richardson
Pharmacological targeting of the integrated protein kinase B, phosphatase and tensin homolog deleted on chromosome 10, and transforming growth factor-beta pathways in prostate cancer.
Molecular pharmacology 2009;75(3):429-36.
2009: Paul V Bernhardt; Philip C Sharpe; Mohammad Islam; David B Lovejoy; Danuta S Kalinowski; Des R Richardson
Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.
Journal of medicinal chemistry 2009;52(2):407-15.
2009: Ján Stariat; Petra Kovaríková; Jirí Klimes; David B Lovejoy; Danuta S Kalinowski; Des R Richardson
HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(3):316-22.
2009: A Bohlken; B B Cheung; Jessica Lilian Bell; J Koach; S Smith; Eric Sekyere; W Thomas; M Norris; Michelle Haber; D B Lovejoy; Des R Richardson; Glenn M Marshall
ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cells.
British journal of cancer 2009;100(1):96-105.
2009: Alex Sheftel; Des R Richardson; Josef Prchal; Prem Ponka
Mitochondrial iron metabolism and sideroblastic anemia.
Acta haematologica 2009;122(2-3):120-33.
2009: Premysl Mladĕnka; Danuta S Kalinowski; Pavlína Haskova; Zuzana Bobrovová; Radomír Hrdina; Tomás Simůnek; Petr Nachtigal; Vladimĺr Semecký; Jaroslava Vávrová; Magdaléna Holeckova; Vladimir Palicka; Yvona Mazurová; Patric J Jansson; Des R Richardson
The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity.
Chemical research in toxicology 2009;22(1):208-17.
2008: Zaklina Kovacevic; Dong Fu; Des R Richardson
The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets.
Biochimica et biophysica acta 2008;1783(10):1981-92.
2008: Veronika Opletalová; Danuta S Kalinowski; Marcela Vejsová; Jirí Kunes; Milan Pour; Josef Jampílek; Vladimír Buchta; Des R Richardson
Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: cellular iron chelation mediating cytotoxic activity.
Chemical research in toxicology 2008;21(9):1878-89.
2008: Megan Whitnall; Robert Sutak; Xiangcong Xu; Erika M Becker; Marc R Mikhael; Prem Ponka; Yohan Suryo Rahmanto; Des R Richardson
The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(28):9757-62.
2008: C K Lim; Danuta S Kalinowski; Des R Richardson
Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Molecular pharmacology 2008;74(1):225-35.
2008: Robert Sutak; Emmanuel Lesuisse; Jan Tachezy; Des R Richardson
Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence.
Trends in microbiology 2008;16(6):261-8.
2008: Robert Sutak; Xiangcong Xu; Megan Whitnall; Mohammed Abul Kashem; Daniel Vyoral; Des R Richardson
Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism.
Proteomics 2008;8(8):1731-41.
2008: Des R Richardson; Hiu Chuen Lok
The nitric oxide-iron interplay in mammalian cells: transport and storage of dinitrosyl iron complexes.
Biochimica et biophysica acta 2008;1780(4):638-51.
2008: X Xu; R Sutak; Des R Richardson
Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Molecular pharmacology 2008;73(3):833-44.
2008: Danuta S Kalinowski; Philip C Sharpe; Paul V Bernhardt; Des R Richardson
Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
Journal of medicinal chemistry 2008;51(2):331-44.
2008: Sebastien Farnaud; Maryam Amini; Chiara Rapisarda; Richard Cammack; Tam Bui; Alex Drake; Robert W Evans; Yohan Suryo Rahmanto; Des R Richardson
Biochemical and spectroscopic studies of human melanotransferrin (MTf): electron-paramagnetic resonance evidence for a difference between the iron-binding site of MTf and other transferrins.
The international journal of biochemistry & cell biology 2008;40(12):2739-45.
2008: Paul V Bernhardt; Gregory J Wilson; Philip C Sharpe; Danuta S Kalinowski; Des R Richardson
Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 2008;13(1):107-19.
2007: Danuta S Kalinowski; Philip C Sharpe; Paul V Bernhardt; Des R Richardson
Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.
Journal of medicinal chemistry 2007;50(24):6212-25.
2007: Barbara Podeszwa; Halina Niedbala; Jaroslaw Polanski; Robert Musiol; Dominik Tabak; J Finster; K Serafin; M Milczarek; J Wietrzyk; Stanislaw Boryczka; W Mol; Josef Jampilek; J Dohnal; D S Kalinowski; Des R Richardson
Investigating the antiproliferative activity of quinoline-5,8-diones and styrylquinolinecarboxylic acids on tumor cell lines.
Bioorganic & medicinal chemistry letters 2007;17(22):6138-41.
2007: Zufan Debebe; Tatyana Ammosova; Marina Jerebtsova; Joseph Kurantsin-Mills; Xiaomei Niu; Sharroya Charles; Des R Richardson; Patricio E Ray; Victor Roland Gordeuk; Sergei Nekhai
Iron chelators ICL670 and 311 inhibit HIV-1 transcription.
Virology 2007;367(2):324-33.
2007: Yohan Suryo Rahmanto; Louise L Dunn; Des R Richardson
Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo.
Carcinogenesis 2007;28(10):2172-83.
2007: Yohan Suryo Rahmanto; Louise L Dunn; Des R Richardson
The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark--from iron metabolism to tumorigenesis.
Oncogene 2007;26(42):6113-24.
2007: Yu Yu; Zaklina Kovacevic; Des R Richardson
Tuning cell cycle regulation with an iron key.
Cell cycle (Georgetown, Tex.) 2007;6(16):1982-94.
2007: Paul V Bernhardt; Piao Chin; Philip C Sharpe; Des R Richardson
Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity.
Dalton transactions (Cambridge, England : 2003) 2007;(30):3232-44.
2007: Danuta S Kalinowski; Yu Yu; Philip C Sharpe; Mohammad Islam; Yi-Tyng Liao; David B Lovejoy; Naresh Kumar; Paul V Bernhardt; Des R Richardson
Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
Journal of medicinal chemistry 2007;50(15):3716-29.
2007: Dong Fu; Des R Richardson
Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion.
Blood 2007;110(2):752-61.
2007: Danuta S Kalinowski; Des R Richardson
Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
Chemical research in toxicology 2007;20(5):715-20.
2007: Effie Nurtjahja-Tjendraputra; Dong Fu; Juanita M Phang; Des R Richardson
Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression.
Blood 2007;109(9):4045-54.
2007: Zlata Mrkvicková; Petra Kovaríková; Jirí Klimes; Danuta Kalinowski; Des R Richardson
Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity.
Journal of pharmaceutical and biomedical analysis 2007;43(4):1343-51.
2007: Des R Richardson; Yohan Suryo Rahmanto
Differential regulation of the Menkes and Wilson disease copper transporters by hormones: an integrated model of metal transport in the placenta.
The Biochemical journal 2007;402(2):e1-3.
2007: Louise L Dunn; Yohan Suryo Rahmanto; Des R Richardson
Iron uptake and metabolism in the new millennium.
Trends in cell biology 2007;17(2):93-100.
2007: Robert Musiol; Josef Jampilek; Katarina Kralova; Des R Richardson; Danuta Kalinowski; Barbara Podeszwa; Jacek Finster; Halina Niedbala; Anna Palka; Jaroslaw Polanski
Investigating biological activity spectrum for novel quinoline analogues.
Bioorganic & medicinal chemistry 2007;15(3):1280-8.
2006: Yu Yu; Jacky Wong; David B Lovejoy; Danuta S Kalinowski; Des R Richardson
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):6876-83.
2006: Zaklina Kovacevic; Des R Richardson
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer.
Carcinogenesis 2006;27(12):2355-66.
2006: Des R Richardson; Philip C Sharpe; David B Lovejoy; Dakshita Senaratne; Danuta S Kalinowski; Mohammad Islam; Paul V Bernhardt
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity.
Journal of medicinal chemistry 2006;49(22):6510-21.
2006: Louise L Dunn; Eric Sekyere; Yohan Suryo Rahmanto; Des R Richardson
The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis.
Carcinogenesis 2006;27(11):2157-69.
2006: Megan Whitnall; Jonathan Howard; Prem Ponka; Des R Richardson
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(40):14901-6.
2006: Megan Whitnall; Des R Richardson
Iron: a new target for pharmacological intervention in neurodegenerative diseases.
Seminars in pediatric neurology 2006;13(3):186-97.
2006: Ralph N Watts; Clare Hawkins; Prem Ponka; Des R Richardson
Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(20):7670-5.
2006: Neil P Davies; Christopher R Chitambar; Yohan Suryo Rahmanto; Des R Richardson
Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates.
The Journal of pharmacology and experimental therapeutics 2006;317(1):153-62.
2006: Eric Sekyere; Louise L Dunn; Yohan Suryo Rahmanto; Des R Richardson
Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo.
Blood 2006;107(7):2599-601.
2006: Paul V Bernhardt; Johan Mattsson; Des R Richardson
Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues.
Inorganic chemistry 2006;45(2):752-60.
2006: David B Lovejoy; Danuta S Kalinowski; Paul V Bernhardt; Des R Richardson
PCTH: a novel orally active chelator for the treatment of iron overload disease.
Hemoglobin 2006;30(1):93-104.
2005: Des R Richardson
24p3 and its receptor: dawn of a new iron age?
Cell 2005;123(7):1175-7.
2005: Danuta S Kalinowski; Des R Richardson
The evolution of iron chelators for the treatment of iron overload disease and cancer.
Pharmacological reviews 2005;57(4):547-83.
2005: Paul V Bernhardt; Piao Chin; Philip C Sharpe; Jing-Yan C Wang; Des R Richardson
Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 2005;10(7):761-77.
2005: H Lennart Persson; Des R Richardson
Iron-binding drugs targeted to lysosomes: a potential strategy to treat inflammatory lung disorders.
Expert opinion on investigational drugs 2005;14(8):997-1008.
2005: X Xu; H L Persson; Des R Richardson
Molecular pharmacology of the interaction of anthracyclines with iron.
Molecular pharmacology 2005;68(2):261-71.
2005: Eric Sekyere; Louise L Dunn; Des R Richardson
Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human.
Biochimica et biophysica acta 2005;1722(2):131-42.
2005: Des R Richardson
More roles for selenoprotein P: local selenium storage and recycling protein in the brain.
The Biochemical journal 2005;386(Pt 2):e5-7.
2005: Ian Napier; Prem Ponka; Des R Richardson
Iron trafficking in the mitochondrion: novel pathways revealed by disease.
Blood 2005;105(5):1867-74.
2005: Des R Richardson
Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer.
Current medicinal chemistry 2005;12(23):2711-29.
2004: C S M Wong; J C Kwok; Des R Richardson
PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
Biochimica et biophysica acta 2004;1739(1):70-80.
2004: Timothy Bede Chaston; Ralph N Watts; Jun Yuan; Des R Richardson
Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7365-74.
2004: Nghia T V Le; Des R Richardson
Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation.
Blood 2004;104(9):2967-75.
2004: Paul V Bernhardt; Piao Chin; Des R Richardson
Iron catalysed assembly of an asymmetric mixed-ligand triple helicate.
Dalton transactions (Cambridge, England : 2003) 2004;(20):3342-6.
2004: Des R Richardson; Evan H Morgan
The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain.
Biochimica et biophysica acta 2004;1690(2):124-33.
2004: Des R Richardson
Iron and neoplasia: serum transferrin receptor and ferritin in prostate cancer.
The Journal of laboratory and clinical medicine 2004;144(4):173-5.
2004: Jun Yuan; David B Lovejoy; Des R Richardson
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.
Blood 2004;104(5):1450-8.
2004: Nghia T V Le; Des R Richardson
Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects.
International journal of cancer. Journal international du cancer 2004;110(3):468-9.
2004: Ralph N Watts; Des R Richardson
Differential effects on cellular iron metabolism of the physiologically relevant diatomic effector molecules, NO and CO, that bind iron.
Biochimica et biophysica acta 2004;1692(1):1-15.
2004: Des R Richardson
Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions.
Annals of the New York Academy of Sciences 2004;1012():326-41.
2004: Asikiya Walcourt; Mark Loyevsky; David B Lovejoy; Victor Roland Gordeuk; Des R Richardson
Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites.
The international journal of biochemistry & cell biology 2004;36(3):401-7.
2004: Des R Richardson
Mysteries of the transferrin-transferrin receptor 1 interaction uncovered.
Cell 2004;116(4):483-5.
2004: J C Kwok; Des R Richardson
Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents.
Molecular pharmacology 2004;65(1):181-95.
2003: Paul V Bernhardt; Lorraine M Caldwell; David B Lovejoy; Des R Richardson
Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde.
Acta crystallographica. Section C, Crystal structure communications 2003;59(Pt 11):o629-33.
2003: Paul V Bernhardt; Lorraine M Caldwell; Timothy Bede Chaston; Piao Chin; Des R Richardson
Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 2003;8(8):866-80.
2003: S X Liang; Des R Richardson
The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.
Carcinogenesis 2003;24(10):1601-14.
2003: Eric Sekyere; Louise L Dunn; Des R Richardson
The double-edged nature of using genetic databases: melanotransferrin genes and transcripts.
FEBS letters 2003;547(1-3):233.
2003: Timothy Bede Chaston; Des R Richardson
Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
American journal of hematology 2003;73(3):200-10.
2003: Cynthia Wong; Des R Richardson
Beta-thalassaemia: emergence of new and improved iron chelators for treatment.
The international journal of biochemistry & cell biology 2003;35(7):1144-9.
2003: Nghia T V Le; Des R Richardson
Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
Carcinogenesis 2003;24(6):1045-58.
2003: D B Lovejoy; Des R Richardson
Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators.
Current medicinal chemistry 2003;10(12):1035-49.
2003: Des R Richardson
The role of hypoxia and nitrogen monoxide in the regulation of cellular iron metabolism.
The Journal of laboratory and clinical medicine 2003;141(5):289-91.
2003: Timothy Bede Chaston; Des R Richardson
Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 2003;8(4):427-38.
2003: J C Kwok; Des R Richardson
Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway.
Molecular pharmacology 2003;63(4):849-61.
2003: Erika M Becker; David B Lovejoy; Judith Greer; Ralph Watts; Des R Richardson
Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.
British journal of pharmacology 2003;138(5):819-30.
2003: Des R Richardson
Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?
Expert opinion on investigational drugs 2003;12(2):235-45.
2003: Ralph N Watts; Prem Ponka; Des R Richardson
Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron.
The Biochemical journal 2003;369(Pt 3):429-40.
2003: Des R Richardson
The biogenesis of [Fe-S] clusters: the role of the unorthodox ABC ATPase, SufC, and the wider implications for understanding iron metabolism.
Redox report : communications in free radical research 2003;8(3):125-7.
2003: Timothy Bede Chaston; David B Lovejoy; Ralph N Watts; Des R Richardson
Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):402-14.
2002: Nghia T V Le; Des R Richardson
The role of iron in cell cycle progression and the proliferation of neoplastic cells.
Biochimica et biophysica acta 2002;1603(1):31-46.
2002: Juliana C Kwok; Des R Richardson
Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity.
Molecular pharmacology 2002;62(4):888-900.
2002: Michael R Food; Eric Sekyere; Des R Richardson
The soluble form of the membrane-bound transferrin homologue, melanotransferrin, inefficiently donates iron to cells via nonspecific internalization and degradation of the protein.
European journal of biochemistry / FEBS 2002;269(18):4435-45.
2002: Des R Richardson
Deferiprone: greater efficacy at depleting myocardial than hepatic iron?
Lancet 2002;360(9332):501-2.
2002: David B Lovejoy; Des R Richardson
Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells.
Blood 2002;100(2):666-76.
2002: Ralph N Watts; Des R Richardson
The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner.
European journal of biochemistry / FEBS 2002;269(14):3383-92.
2002: Des R Richardson
Iron chelators as therapeutic agents for the treatment of cancer.
Critical reviews in oncology/hematology 2002;42(3):267-81.
2002: Erika M Becker; Judith Greer; Prem Ponka; Des R Richardson
Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization.
Blood 2002;99(10):3813-22.
2002: Juliana C Kwok; Des R Richardson
The iron metabolism of neoplastic cells: alterations that facilitate proliferation?
Critical reviews in oncology/hematology 2002;42(1):65-78.
2002: Eric Sekyere; Michael R Food; Des R Richardson
A second melanotransferrin gene (MTf2) and a novel protein isoform: explanation for the membrane-bound and soluble forms of melanotransferrin?
FEBS letters 2002;512(1-3):350-2.
2002: Nghia T V Le; Des R Richardson
Ferroportin1: a new iron export molecule?
The international journal of biochemistry & cell biology 2002;34(2):103-8.
2002: Des R Richardson
Therapeutic potential of iron chelators in cancer therapy.
Advances in experimental medicine and biology 2002;509():231-49.
2002: S L Wardrop; C Wells; Timothy Ravasi; David A Hume; Des R Richardson
Induction of Nramp2 in activated mouse macrophages is dissociated from regulation of the Nramp1, classical inflammatory genes, and genes involved in iron metabolism.
Journal of leukocyte biology 2002;71(1):99-106.
2001: Paul V Bernhardt; Piao Chin; Des R Richardson
Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 2001;6(8):801-9.
2001: Des R Richardson
The controversial role of deferiprone in the treatment of thalassemia.
The Journal of laboratory and clinical medicine 2001;137(5):324-9.
2001: Des R Richardson
Iron and gallium increase iron uptake from transferrin by human melanoma cells: further examination of the ferric ammonium citrate-activated iron uptake process.
Biochimica et biophysica acta 2001;1536(1):43-54.
2001: Des R Richardson
Cloning of the ferrireductase that may be involved in iron transport in the small intestine: revisiting Crane's controversial oxidoreductase.
Redox report : communications in free radical research 2001;6(3):133-5.
2000: E Sekyere; Des R Richardson
The membrane-bound transferrin homologue melanotransferrin: roles other than iron transport?
FEBS letters 2000;483(1):11-6.
2000: David B Lovejoy; Des R Richardson; Paul V Bernhardt
2-hydroxy-1-naphthaldehyde 2-methylthiosemicarbazone.
Acta crystallographica. Section C, Crystal structure communications 2000;56 ( Pt 3)():341-2.
2000: Des R Richardson
The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell.
European journal of biochemistry / FEBS 2000;267(5):1290-8.
2000: J C Kwok; Des R Richardson
The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.
Redox report : communications in free radical research 2000;5(6):317-24.
1999: Des R Richardson; E Becker; Paul V Bernhardt
The biologically active iron chelators 2-pyridylcarboxaldehyde isonicotinoylhydrazone, 2-pyridylcarboxaldehyde benzoylhydrazone monohydrate and 2-furaldehyde isonicotinoylhydrazone.
Acta crystallographica. Section C, Crystal structure communications 1999;55 ( Pt 12)():2102-5.
1999: E Becker; Des R Richardson
Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
The Journal of laboratory and clinical medicine 1999;134(5):510-21.
1999: Des R Richardson
Role of ceruloplasmin and ascorbate in cellular iron release.
The Journal of laboratory and clinical medicine 1999;134(5):454-65.
1999: Grant A Darnell; Des R Richardson
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Blood 1999;94(2):781-92.
1999: Des R Richardson; Paul V Bernhardt
Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 1999;4(3):266-73.

FIND

DISCOVER

PROMOTE

Des Richardson

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Living Beings

Phenomena

Concepts & Ideas

Procedures

Disorders

Genes & Molecular Sequences